Merck Ends Nemtabrutinib Program After Phase 3 Review

Company Merck Event Type Phase 3 program discontinuation (previously missed 17 Nov release) Modality Reversible noncovalent BTK inhibitor Asset Nemtabrutinib (MK-1026) Target BTK Disease Area CLL, SLL and other hematologic cancers Summary Merck discontinued the full BELLWAVE nemtabrutinib program for CLL, SLL and other hematologic…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *